Navigation Links
GenVec Reports Second Quarter 2009 Financial Results
Date:8/6/2009

Operating expenses were $8.6 million and $17.8 million for the three-month and six-month periods ended June 30, 2009, respectively, representing decreases of 20 percent and 14 percent as compared to $10.6 million and $20.8 million in the comparable prior year periods. The decrease in both periods is primarily due to lower personnel costs, reduced patient, site, lab, data management, monitoring and materials costs related to our TNFerade(TM) program, reduced materials costs related to our funded programs, and reduced general lab materials and supplies. Also contributing to the decrease are lower professional, facility, and recruiting costs. These decreases are partially offset in both periods by increases related to the manufacturing costs of TNFerade arising from the letter agreement and subsequent termination of our Cobra contract and increases related to manufacturing costs related to our FMD program as compared to the prior year periods.

GenVec ended the second quarter of 2009 with $12.6 million in cash and investments.

"Based on existing contracts and collaborations, we anticipate revenues for 2009 will be between $15.0 million and $18.0 million. We project our cash burn to be between $8.0 million and $11.0 million for the 12 months ending June 30, 2010," commented Douglas J. Swirsky, GenVec's Senior Vice President and Chief Financial Officer. "In spite of the difficult economic times, GenVec continues to make strides in its therapeutic and vaccine programs. We look forward to sharing additional data from our pivotal trial in locally-advanced pancreatic cancer early next year."

Second Quarter and Recent Highlights

TNFerade for Cancer

  • As of July 31, 2009, 262 patients have been enrolled in the GenVec's pivotal PACT trial.

  • GenVec presented data on its PACT trial at the annual mee
    '/>"/>

SOURCE GenVec, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. GenVec Expands Contract Supporting Malaria Vaccine Program
2. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
3. InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
4. SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
5. OncoGenex Reports Second Quarter 2009 Financial Results
6. Repligen Reports First Quarter Fiscal Year 2010 Financial Results
7. PDI Reports 2009 Second Quarter Financial Results
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
10. NxStage Reports Second Quarter 2009 Financial Results
11. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DUBLIN , Oct. 22, 2014 ... "Organic Electronics Market by Material, by Application, Geography ... report to their offering. Organic electronics, ... a branch of material science which deals with small ... as organic because small molecules and polymers are carbon ...
(Date:10/20/2014)... 2014 Convey Computer , the ... from Iowa State University won first place in the ... Convey HC-2ex, the team’s solution achieved the highest overall ... the second place finisher. , Experts from all segments ... month long challenge, using a variety of design tools, ...
(Date:10/20/2014)... Oct. 20, 2014  GenVec, Inc. (NASDAQ: GNVC ... , Ph.D., from its board of directors effective on October ... 2003, and served as its chairman from June 2006 to ... Nominating and Corporate Governance and Audit Committees of the board.  ... a decade of dedicated service to GenVec, and its stockholders," ...
(Date:10/20/2014)... Tigard, OR (PRWEB) October 20, 2014 ... to participate in an investigational study of donor stem ... nationally in stem cell therapy and has performed clinical ... of this study is to determine if a single ... arthritically affected joints can help reduce pain and inflammation ...
Breaking Biology Technology:Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... KEELE, England, July 27 ... developed by the Pioneering Orthobiologics,Company, Biocomposites, ( ... superior bone regenerative properties due,to its unique negative ... The research carried out by the hospital ...
... 27 Micromet, Inc. (Nasdaq: MITI ), a ... cancer, inflammation and autoimmune diseases, today announced that it will ... 6, 2009, at 9:00 am Eastern Time (3:00 pm Central ... quarter of 2009. Micromet anticipates releasing its financial results at ...
... , MADISON, N.J., July 24 Quest ... of diagnostic testing, information and services, today announced that the U.S. ... to the company,s Focus Diagnostics business for its test for detecting ... of influenza A virus initially referred to as the swine flu ...
Cached Biology Technology:Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts 2Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009 2Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009 3Micromet, Inc. to Host Conference Call and Webcast to Report Second Quarter 2009 Financial Results on August 6, 2009 4FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 2FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 3FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 4FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business 5
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... can be cultivated efficiently, they are anything but ... by monoculture cultivation is becoming increasingly evident. Despite ... form and are regarded as the sole possibility ... quite wrongfully, finds Bernhard Schmid, an ecology professor ... novel form of agriculture and forestry. After all, ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... 3dMD, the 3D surface imaging system and software developer ... than a decade, announces the availability of its recently ... support serious research into quantifying and measuring human anatomical ... focused on generating virtual avatar effects for application in ...
... data at unprecedented speeds. Making sense of these ... databases is an increasingly difficult and complex task. ... Philip Morris International (PMI) R&D launched a project ... Research) in May with the aim of challenging ...
... of pregnancy and the major cause of death for both ... about one in 20 pregnancies. The main symptoms are high ... preeclampsia is still unclear. Dr. Florian Herse (Experimental and Clinical ... the Charit), Dr. Ralf Dechend (ECRC and Helios Klinikum Berlin-Buch) ...
Cached Biology News:3dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging 23dMD Transitions Anatomical Research from 3D-Static to 4D-Movement Surface Imaging 3An international competition reaffirms the potential of bioinformatics in the diagnosis of disease 2New risk factor identified for high blood pressure during pregnancy 2New risk factor identified for high blood pressure during pregnancy 3New risk factor identified for high blood pressure during pregnancy 4
8 different frozen tissues are mounted on positively charged glass slides...
... BioChain's monkey normal multiple tissue panels ... cellular localization of genes or proteins ... Tissues are mounted on positively charged ... are available in the identical format, ...
... T2-04 is an ultra-compact pump available in single ... and ideal for use in portable air and ... this pump works well in environments where DC ... compact size are critical., Offers ultra-compact size, ...
XA7 B6...
Biology Products: